Free Trial
LON:DXRX

Diaceutics (DXRX) Share Price, News & Analysis

Diaceutics logo
GBX 124.81 -0.69 (-0.55%)
As of 06/13/2025 11:52 AM Eastern

About Diaceutics Stock (LON:DXRX)

Key Stats

Today's Range
124.81
126
50-Day Range
108
140
52-Week Range
106
151
Volume
34,172 shs
Average Volume
123,298 shs
Market Capitalization
£105.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 160
Consensus Rating
Buy

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

DXRX Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Diaceutics (LON:DXRX) Shares Up 2.3% - Should You Buy?
See More Headlines

DXRX Stock Analysis - Frequently Asked Questions

Diaceutics' stock was trading at GBX 123 on January 1st, 2025. Since then, DXRX shares have increased by 1.5% and is now trading at GBX 124.81.
View the best growth stocks for 2025 here
.

Diaceutics PLC (LON:DXRX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($2.02) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative trailing twelve-month return on equity of 7.15%.

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Company Calendar

Last Earnings
5/13/2025
Today
6/14/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
LON:DXRX
CIK
N/A
Phone
N/A
Fax
N/A
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 160
High Stock Price Target
GBX 160
Low Stock Price Target
GBX 160
Potential Upside/Downside
+28.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
123.48
P/E Growth
N/A
Net Income
-£2.84 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£26.08 million
Cash Flow
GBX 40.01 per share
Price / Cash Flow
3.12
Book Value
GBX 45.87 per share
Price / Book
2.72

Miscellaneous

Free Float
N/A
Market Cap
£105.33 million
Optionable
Not Optionable
Beta
0.58
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (LON:DXRX) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners